16/01-2023 - Christoph STEIN-THOERINGER : On the role of the gut microbiome in the efficacy of CAR-T cell immunotherapy

11 - Janvier - 2023


Bâtiment Kourilsky - 13h–14h

Salle des Conférences (Rez de Chaussée),

184 rue du Faubourg Saint-Antoine, Paris



On the role of the gut microbiome in the efficacy of CAR-T cell immunotherapy


Professor for Infectious Diseases and Translational Microbiome Sciences - Internal Medicine I, University Clinic Tuebingen Infectious Disease Section and Translational Microbiome Lab

invitée par Equipe de Mohamad MOTHY (Equipe MOTHY (florent.malard@yahoo.fr))


The gut microbiome and factors such as antibiotics or diet affecting its composition are increasingly recognized to affect the efficacy and toxicity of immunotherapies. Treatment with CD19-directed chimeric antigen receptor T cells (CARTs) represents a novel approach in cancer therapy that aims to boost antitumor immunity against relapsed or progressive lymphoid malignancies. Following previous studies on the importance of the gut microbiome in adoptive T cell transfer therapies, we performed an international, multicentric clinical trial with centers in Germany and the US studying the effects of antibiotic treatment and gut microbiome features associated with clinical outcomes. In synopsis, we observed that broad-spectrum antibiotic administration shortly before or around CAR-T cell infusion significantly reduces overall survival and increase the incidence of tumor progression in lymphoma patients. Despite an association with microbiome dysbiosis, antibiotic treatment is identified as a surrogate for disease severity and an increased inflammatory state; it significantly interferes with the ability of microbiome features to predict clinical outcomes applying AI algorithms. However, excluding these events from our machine-learning analyses uncovers a specific gut microbiome signature at baseline that is able to segregate long-term response to CAR-T immunotherapy. We also found that a specific microbiome signature is associated with CAR-T cell expansion, persistence and exhaustion phenotypes along changes in the serum cytokine milieu.
Despite a clear mechanisms provided, we can show for the first time the there is an intricate relationship between a patient’s microbiome and the efficacy of CAR-T cells against lymphoma providing the necessity for “microbiome stewardship” in cancer patients.



Afin d'assister à cette conférence vous pourrez vous connecter sur le lien zoom suivant :

Heure : 16 janv. 2023 01:00 PM Paris

Participer à la réunion Zoom

ID de réunion : 876 1888 6466
Code secret : 160123

Une seule touche sur l’appareil mobile
+33186995831,,87618886466#,,,,*160123# France
Composez un numéro en fonction de votre emplacement
+33 1 8699 5831 France
+49 695 050 2596 Allemagne
ID de réunion : 876 1888 6466
Code secret : 160123
Trouvez votre numéro local : https://us06web.zoom.us/u/kcWADASceo

Hôpital St-Antoine

Bâtiment Kourilsky
34 rue Crozatier
75012 PARIS

Sorbonne Université
27 rue Chaligny
75012 PARIS

Ce site utilise des cookies et vous donne le contrôle sur ce que vous souhaitez activer Tout accepter Personnaliser